Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinblastine and Temsirolimus in Pediatric Recurrent/Refractory Tumors
NCT02343718Phase 1Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jun 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of temsirolimus in solid tumor, lymphoma and central nervous system tumor, sponsored by Canadian Cancer Trials Group. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 4 years. Started Jun 2015; status: completed.
02
Drugs
temsirolimus
03
Conditions
solid tumorlymphomacentral nervous system tumor
Beyond the preview
Go deeper on NCT02343718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02343718.